Hung -Gu Oil Ltd (KOSDAQ:024060)
South Korea · Delayed Price · Currency is KRW 12,400
-100 (-0.80%)
At close: Aug 7, 2025, 3:30 PM KST
Achilles Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Operating Revenue | 115,641 | 116,852 | 126,695 | 146,718 | 132,214 | 114,844 | Upgrade |
Other Revenue | - | - | -0 | - | - | - | Upgrade |
Revenue | 115,641 | 116,852 | 126,695 | 146,718 | 132,214 | 114,844 | Upgrade |
Revenue Growth (YoY) | -9.53% | -7.77% | -13.65% | 10.97% | 15.13% | -23.78% | Upgrade |
Cost of Revenue | 109,905 | 111,137 | 120,581 | 139,095 | 125,801 | 108,914 | Upgrade |
Gross Profit | 5,736 | 5,716 | 6,115 | 7,623 | 6,413 | 5,929 | Upgrade |
Selling, General & Admin | 4,876 | 4,847 | 4,906 | 4,979 | 5,569 | 5,437 | Upgrade |
Other Operating Expenses | 616.9 | 616.9 | 619.17 | 547.51 | 483.91 | 579.58 | Upgrade |
Operating Expenses | 6,027 | 5,998 | 6,028 | 5,938 | 6,442 | 6,423 | Upgrade |
Operating Income | -290.63 | -282.77 | 86.98 | 1,685 | -28.82 | -493.8 | Upgrade |
Interest Expense | -423.06 | -423.06 | -450.61 | -78.74 | - | - | Upgrade |
Interest & Investment Income | 20.6 | 20.6 | 27.01 | 45.42 | 12.23 | 128.69 | Upgrade |
Other Non Operating Income (Expenses) | 1,531 | 1,470 | 1,577 | 1,152 | 1,375 | 1,744 | Upgrade |
EBT Excluding Unusual Items | 838.31 | 784.51 | 1,240 | 2,804 | 1,358 | 1,379 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | 471.02 | 428.62 | 299.83 | Upgrade |
Gain (Loss) on Sale of Assets | -27.55 | -27.55 | 161.22 | 172.9 | 4.69 | 4,509 | Upgrade |
Pretax Income | 810.76 | 756.96 | 1,401 | 3,448 | 1,792 | 6,188 | Upgrade |
Income Tax Expense | 147.79 | 136.55 | 271.96 | 790.49 | 392.91 | 1,396 | Upgrade |
Net Income | 662.97 | 620.41 | 1,129 | 2,657 | 1,399 | 4,791 | Upgrade |
Net Income to Common | 662.97 | 620.41 | 1,129 | 2,657 | 1,399 | 4,791 | Upgrade |
Net Income Growth | -20.13% | -45.06% | -57.50% | 89.95% | -70.80% | -42.22% | Upgrade |
Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 15 | Upgrade |
Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | 15 | Upgrade |
EPS (Basic) | 45.59 | 42.67 | 77.66 | 182.73 | 96.20 | 329.51 | Upgrade |
EPS (Diluted) | 45.59 | 42.67 | 77.66 | 182.73 | 96.20 | 329.51 | Upgrade |
EPS Growth | -20.13% | -45.06% | -57.50% | 89.95% | -70.80% | -42.22% | Upgrade |
Free Cash Flow | 1,482 | 2,267 | 2,472 | -27,654 | -900.51 | 1,617 | Upgrade |
Free Cash Flow Per Share | 101.95 | 155.93 | 170.02 | -1901.82 | -61.93 | 111.21 | Upgrade |
Gross Margin | 4.96% | 4.89% | 4.83% | 5.20% | 4.85% | 5.16% | Upgrade |
Operating Margin | -0.25% | -0.24% | 0.07% | 1.15% | -0.02% | -0.43% | Upgrade |
Profit Margin | 0.57% | 0.53% | 0.89% | 1.81% | 1.06% | 4.17% | Upgrade |
Free Cash Flow Margin | 1.28% | 1.94% | 1.95% | -18.85% | -0.68% | 1.41% | Upgrade |
EBITDA | 475.57 | 475.39 | 812.97 | 2,270 | 510.59 | 16.31 | Upgrade |
EBITDA Margin | 0.41% | 0.41% | 0.64% | 1.55% | 0.39% | 0.01% | Upgrade |
D&A For EBITDA | 766.2 | 758.16 | 725.99 | 584.99 | 539.4 | 510.11 | Upgrade |
EBIT | -290.63 | -282.77 | 86.98 | 1,685 | -28.82 | -493.8 | Upgrade |
EBIT Margin | -0.25% | -0.24% | 0.07% | 1.15% | -0.02% | -0.43% | Upgrade |
Effective Tax Rate | 18.23% | 18.04% | 19.41% | 22.93% | 21.93% | 22.57% | Upgrade |
Advertising Expenses | - | 12.28 | 13.42 | 15.15 | 15.97 | 14.71 | Upgrade |
Updated Mar 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.